Page last updated: 2024-11-05

phenylglycidyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylglycidyl ether (PGE) is an epoxide compound that is widely used as a reactive diluent and curing agent in various industries. It is synthesized through the reaction of phenol with epichlorohydrin. PGE exhibits excellent adhesion properties, low viscosity, and good chemical resistance, making it valuable in epoxy resin formulations. Its effects include enhancing the flexibility, toughness, and adhesion properties of epoxy resins. The compound is studied extensively due to its potential applications in coatings, adhesives, composites, and electronic materials. Notably, PGE has shown promise in the development of high-performance coatings for aerospace and automotive applications. Its importance lies in its ability to contribute to the development of durable, robust, and environmentally friendly materials.'

phenylglycidyl ether: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID31217
CHEMBL ID1568222
CHEBI ID82367
SCHEMBL ID31220
MeSH IDM0065793

Synonyms (99)

Synonym
LS-13614
nsc-53476
nsc53476
phenylglycidyl ether
2-(phenoxymethyl)oxirane
propane, 1,2-epoxy-3-phenoxy-
NCGC00091629-01
einecs 204-557-2
(+/-)-1,2-epoxy-3-phenoxypropane
ageflex pge
ai3-13109
phenol-glycidaether [german]
hsdb 1821
ether, 2,3-epoxypropyl phenyl
brn 0002744
nsc 53476
heloxy wc-63
(+/-)-(2,3-epoxypropyl)phenylether
ccris 738
benzene, (2,3-epoxypropoxy)-
2,3-epoxy-1-phenoxypropane
fenyl-glycidylether [czech]
oxirane, (phenoxymethyl)-
(phenoxymethyl)oxirane
fenyl-glycidylether
glycidol phenyl ether
2,3-epoxypropyl phenyl ether
propane,2-epoxy-3-phenoxy-
glycidyl phenyl ether
oxirane, (phenoxymethyl)-phenol-glycidaether
ether,3-epoxypropyl phenyl
122-60-1
PGE ,
1,2-epoxy-3-phenoxypropane
3-phenoxy-1,2-epoxypropane
3-phenyloxy-1,2-epoxypropane
nsc-635
nsc635
phenol glycidyl ether
phenylglycydyl ether
3-phenoxy-1,2-propylene oxide
phenoxypropylene oxide
wln: t3otj b1or
.gamma.-phenoxypropylene oxide
1-phenoxy-2,3-epoxypropane
ether, phenylglycidyl
oxirane,(phenoxymethyl)-phenol-glycidaether
phenyl 2,3-epoxypropyl ether
phenoxypropene oxide
phenyl glycidyl ether
1,2-epoxy-3-phenoxypropane, technical grade
1,2-epoxy-3-phenoxypropane, 99%
AKOS000200354
smr001372022
MLS002454439
G0098
STK803248
NCGC00091629-02
2-(phenoxy-methyl)-oxirane
oxirane, 2-(phenoxymethyl)-
ec 204-557-2
44kjq1655i ,
5-17-03-00013 (beilstein handbook reference)
unii-44kjq1655i
phenol-glycidaether
C19291
HMS3039J13
cas-122-60-1
dtxsid8021145 ,
dtxcid501145
tox21_200289
NCGC00257843-01
CHEMBL1568222
chebi:82367 ,
FT-0631703
25265-27-4
phenyl glycidyl ether [hsdb]
phenyl glycidyl ether [iarc]
1,2-epoxy-3-phenoxy-propane
2-phenoxymethyl-oxirane
phenoxymethyloxirane
1,2-epoxy-3-phenoxy propane
2,3-epoxypropoxybenzene
(+/-)-3-phenoxy-1,2-epoxypropane
AKOS016050025
SCHEMBL31220
3-phenyloxy-1,2-epoxypropanel-, (.+/-.)-
(.+/-.)-1,2-epoxy-3-phenoxypropane
(.+/-.)-(phenoxymethyl)oxirane
2-(phenoxymethyl)oxirane #
J-521413
F1995-0399
mfcd00005133
EN300-18212
Z57358969
SY246293
mfcd31699959
Q2257129
F87291
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.38720.004023.8416100.0000AID485290
USP1 protein, partialHomo sapiens (human)Potency25.11890.031637.5844354.8130AID743255
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency42.71440.003041.611522,387.1992AID1159552; AID1159553; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency24.41080.005428.02631,258.9301AID1346982
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency58.51400.001024.504861.6448AID743212; AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency55.14940.023723.228263.5986AID743222
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.878719.739145.978464.9432AID1159509
heat shock protein beta-1Homo sapiens (human)Potency55.14940.042027.378961.6448AID743210
gemininHomo sapiens (human)Potency0.36630.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID636078Cytotoxicity against CHO cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID636075Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID636076Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (15.38)18.7374
1990's8 (20.51)18.2507
2000's10 (25.64)29.6817
2010's13 (33.33)24.3611
2020's2 (5.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.94 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.56%)4.05%
Observational0 (0.00%)0.25%
Other38 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]